资源描述：
《A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。
1、CancerBiology&TherapyISSN:1538-4047(Print)1555-8576(Online)Journalhomepage:http://www.tandfonline.com/loi/kcbt20AphaseIIstudyofcapecitabinepluscisplatininmetastatictriple-negativebreastcancerpatientspretreatedwithanthracyclinesandtaxanesQiaoLi,QingLi,PinZhang,PengYuan,JiayuWang,FeiMa,YangLuo
2、,YingFan,RuigangCai&BingheXuTocitethisarticle:QiaoLi,QingLi,PinZhang,PengYuan,JiayuWang,FeiMa,YangLuo,YingFan,RuigangCai&BingheXu(2015):AphaseIIstudyofcapecitabinepluscisplatininmetastatictriple-negativebreastcancerpatientspretreatedwithanthracyclinesandtaxanes,CancerBiology&Therapy,DOI:10.1
3、080/15384047.2015.1095400Tolinktothisarticle:http://dx.doi.org/10.1080/15384047.2015.1095400Acceptedonline:15Oct2015.SubmityourarticletothisjournalViewrelatedarticlesViewCrossmarkdataFullTerms&Conditionsofaccessandusecanbefoundathttp://www.tandfonline.com/action/journalInformation?journalCod
4、e=kcbt20AphaseIIstudyofcapecitabinepluscisplatininmetastatictriple-negativebreastcancerpatientspretreatedwithanthracyclinesandtaxanes11111111QiaoLi,QingLi,PinZhang,PengYuan,JiayuWang,FeiMa,YangLuo,YingFan&Ruigang11,*Cai,BingheXu1DepartmentofMedicalOncology;CancerHospital,ChineseAcademyofMedi
5、calSciences(CAMS)andPekingUnionMedicalCollege;Beijing,ChinaCorrespondenceto:B.H.Xu;Email:xubinghe@medmail.com.cnAbstractBackground:Cisplatinisaneffectiveagentfortriple-negativebreastcancer(TNBC)andsynergisticactivitybetweencisplatinandcapecitabinehasbeendemonstratedbyinvitroandinvivostudies.
6、Thisstudywasdesignedasaprospectiveclinicaltrialtoevaluatetheefficacyandsafetyofcapecitabinepluscisplatin(XP)regimeninmetastaticTNBCpatientspretreatedwithanthracyclinesandtaxanes.PatientsandMethods:Thirty-threepatientswithmetastaticTNBCwhohadanthracyclinesand2taxanesaspriortherapyweretreatedw
7、ithcapecitabine2000mg/morallyonday1through142pluscisplatin75mg/mintravenouslyonday1ofa21-daycycle,followedbycapecitabinemaintenancemedicationsafteramaximumof6cycles.Theprimaryendpointwasobjectiveresponserate(ORR)andthesecondaryendpointsincludedprog
